Nivolumab-induced colitis in a patient with malignant melanoma: A case report and immunological analysis.

J Dermatol　46,P.e339-e341　/　2019

Miyashita A, Fukushima S, Tsukamoto H, Itai H, Miyamoto H, Nakahara S, Kubo Y, Kimura T, Kuriyama H, Ihn H

Hepatitis C virus recurrence in two patients who achieved sustained viral response with interferon-free direct-acting antiviral therapy: reinfection or relapse?

Clin J Gastroenterol　12,P.598-302　/　2019

Yukawa Y, Tamori A, Iio E, Ogawa S, Yoshida K, Uchida-Kobayashi S, Enomoto M, Tanaka Y, Kawada N.

Factors influencing subclinical atherosclerosis in patients with biopsy-proven nonalcoholic fatty liver disease.

PLoS One　14,P.e0224184　/　2019

Arai T, Atsukawa M, Tsubota A, Kawano T, Koeda M, Yoshida Y, Tanabe T, Okubo T, Hayama K, Iwashita A, Itokawa N, Kondo C, Kaneko K, Kawamoto C, Hatori T, Emoto N, Iio E, Tanaka Y, Iwakiri K.

Hepatitis B virus-related hepatocellular carcinoma in young adults Efficacy of nationwide selective vaccination.

Hepatol Res　50,P.182-189　/　2019

Yotsuyanagi H, Takano T, Tanaka M, Amano K, Imamura M, Ogawa K, Yasunaka T, Yasui Y, Hayashi K, Tanaka Y, Tajiri H; for Japanese adolescent HBV-HCC study group.

Factors associated with longitudinal changes in serum concentrations of Mac-2 binding protein: a prospective 3-year observational study

Nutr Metab Cardiovasc Dis　29,P.1337-1344　/　2019

Sugiura T, Dohi Y, Takase H, Yamashita S, Tsuzuki Y, Ogawa S, Tanaka Y, Ohte N.

Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway

J Hematol Oncol.　12,P.144-144　/　2019

Ogawa K,Lin Q,LiLe,Bai X,Chen X,Chen H,Kong R,Wang Y,Zhu H,He F,Xu Q,Liu L,Li M,Zhang S, Nagaoka K,Carlson R,Safran H,Charpentier K,Sun B,Wands J,Dong

The reduction of miR146b-5p in monocytes and T cells could contribute to the immunopathogenesis of hepatitis C virus infection.

Sci Rep　9,P.13393　/　2019

Kondo Y, Kogure T, Ninomiya M, Fukuda R, Monma N, Ikeo K, Tanaka Y.

Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium

Hepatol Int　13,P.587-598　/　2019

Huang C-F, Iio E, Jun DW, Ogawa E, Toyoda H, Hsu Y-C, Haga H, Iwane S, Enomoto M, Lee DH, Wong G, Liu C-H, Tada T, Chuang W-L, Cheung R, Hayashi J, Tseng C-H, Yasuda S, Tran S, Kam L, Henry L, Jeong JY, Nomura H, Park SH, Nakamuta M, Huang J-F, Tai C-M, Lo G-H, Lee M-H, Yang H-I, Kao J-H, Tamori A, Eguchi Y, Ueno Y, Furusyo N, Tanaka Y, Yu M-L, Nguyen MH, For the REAL-C Investigators

MEG3-derived miR-493-5p overcomes the oncogenic feature of IGF2-miR-483 loss of imprinting in hepatic cancer cells

Cell Death Dis　10,P.553　/　2019

Gailhouste L, Liew LC, Yasukawa K, Hatada I, Tanaka Y, Kato T, Nakagama H, Ochiya T

Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naïve noncirrhotic HCV genotype 1 and 2infected patients in a real-world setting in Japan.

J Viral Hepat　26,P.1266-1275　/　2019

Ikeda H, Waanabe T, Atsukawa M, Toyoda H, Takaguchi K, Nakamuta M, Matsumoto N, Okuse C, Tada T, Tsutsui A, Yamashita N, Kondo C, Hayama K, Kato K, Itokawa N, Arai T, Shimada N, Asano T, Uojima H, Ogawa C, Mikami S, Ikegami T, Fukunishi S, Asai A, Iio E, Tsubota A, Hiraoka A, Nozaki A, Okubo H, Tachi Y, Moriya A, Oikawa T, Matsumoto Y, Tsuruoka S, Tani J, Kikuchi K, Iwakiri K, Tanaka Y, Kumada T.

Eltrombopag enables initiation and completion of pegylated interferon/ribavirin therapy in Japanese HCV-infected patients with chronic liver disease and thrombocytopenia

Exp. Ther. Med　18,P.596-604　/　2019

Kawaguchi T, Komori A, Fujisaki K, Nishiguchi S,Kato M,Takagi H, Tanaka Y, Notsumata K, Mita E, Nomura H,Shibakoge M,Takaguchi K, Hattori T, Sata M, Koike K

Bardoxolone methyl as a novel potent antiviral agent against hepatitis B and C viruses in human hepatocyte cell culture systems.

Antiviral Res　169,P.104537　/　2019

Nio Y, Sasai M, Akahori Y, Okamura H, Hasegawa H, Oshima M, Watashi K, Wakita T, Ryo A, Tanaka Y, Hijikata M

Trends and Efficacy of Interferon-Free Anti–hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan

Open Forum Infect Dis　6,P.ofz185　/　2019

Toyoda H, Atsukawa M, Uojima H, Nozaki A, Tamai H, Takaguchi K, Fujioka S, Nakamuta M, Tada T, Yasuda S, Chuma M, Senoh T, Tsutsui A, Yamashita N, Hiraoka A, Michitaka K, Shima T, Akahane T, Itobayashi E, Watanabe T, Ikeda H, Iio E, Fukunishi S, Asano T, Tachi Y, Ikegami T, Tsuji K, Abe H, Kato K, Mikami S, Okubo H, Shimada N, Ishikawa T, Matsumoto Y, Itokawa N, Arai T, Tsubota A, Iwakiri K, Tanaka Y, Kumada T

Small Interfering RNA Screening for the Small GTPase Rab Proteins Identifies Rab5B as a Major Regulator of Hepatitis B Virus Production

J Virol　93,P.e00621　/　2019

Inoue J, Ninomiya M, Umetsu T, Nakamura T, Kogure T, Kakazu E, Iwata T, Takai S, Sano A, Fukuda M, Watashi K, Isogawa M, Tanaka Y, Shimosegawa T, McNiven MA, Masamune A

Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma

Cancer Lett　449,P.87-98　/　2019

Nagaoka K, Bai X, Ogawa K, Dong X, Zhang S, Zhou Y, Carlson RI, Jiang ZG, Fuller S, Lebowitz MS, Ghanbari H, Wands JR

Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis

J Hepatol　71,P.473-485　/　2019

Ji F, Yeo YH, Wei MT, Ogawa E, Enomoto M, Lee DH, Iio E, Lubel J, Wang W, Wei B, Ide T, Preda CM, Conti F, Minami T, Bielen R, Sezaki H, Barone M, Kolly P, Chu P-S, Virlogeux V, Eurich D, Henry L, Bass MB, Kanai T, Dang S, Li Z, Dufour J-F, Zoulim F, Andreone P, Cheung RC, Tanaka Y, Furusyo N, Toyoda H, Tamori A, Nguyen MH

Mac-2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients With Chronic Hepatitis B or C Infection

Hepatol Commun　3,P.493-503　/　2019

Jun T, Hsu YC, Ogawa S, Huang YT, Yeh ML, Tseng CH, Huang CF, Tai CM, Dai CY, Huang JF, Chuang WL, Yu ML, Tanaka Y, Nguyen MH

Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization

Proc Natl Acad Sci U S A　116,P.8487-8492　/　2019

Iwamoto M, Saso W, Sugiyama R, Ishii K, Ohki M, Nagamori S, Suzuki R, Aizaki H, Ryo A, Yun JH, Park SY, Ohtani N, Muramatsu M, Iwami S, Tanaka Y, Sureau C, Wakita T, Watashi K

Clinical evaluation of a newly developed chemiluminescent enzyme immunoassay in Japan for hepatitis C virus core antigen.

Jpn J Infect Dis　72,P.285-291　/　2019

Inoue T, Ohike T, Ohne K, Sato S, Goto T, Tanaka Y.

The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study.

Aliment Pharmacol Ther　49,P.1230-1241　/　2019

Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, Michitaka K, Ikegami T, Nozaki A, Uojima H, Fukunishi S, Genda T, Abe H, Hotta N, Tsuji K, Ogawa C, Tachi Y, Shima T, Shimada N, Kondo C, Akahane T, Aizawa Y, Tanaka Y, Kumada T, Iwakiri K.

Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately. A

Ann Surg Oncol　26,P.1385-1393　/　2019

Yoshida T, Hijioka S, Hosoda W, Ueno M, Furukawa M, Kobayashi N, Ikeda M, Ito T, Kodama Y, Morizane C, Notohara K, Taguchi H, Kitano M, Yane K, Tsuchiya Y, Komoto I, Tanaka H, Tsuji A, Hashigo S, Mine T, Kanno A, Murohisa G, Miyabe K, Takagi T, Matayoshi N, Sakaguchi M, Ishii H, Kojima Y, Matsuo K, Yoshitomi H, Nakamori S, Yanagimoto H, Yatabe Y, Furuse J, Mizuno N.

The antiviral effects of human microRNA miR-302c-3p against hepatitis B virus infection.

Aliment Pharmacol Ther　49,P.1060-1070　/　2019

Hamada-Tsutsumi S, Naito Y, Sato S, Takaoka A, Kawashima K, Isogawa M, Ochiya T, Tanaka Y

CMCDG, a novel nucleoside analog with favorable safety features, exerts potent activity against wild-type and entecavir-resistant hepatitis B virus

Antimicrob Agents Chemother　63,P.e02143　/　2019

Higashi-Kuwata N, Hayashi S, Das D, Kohgo S, Murakami S, Hattori S-I, Imoto S, Venzon DJ, Singh K, Sarafianos SG, Tanaka Y, Mitsuya H

Influence of renal dysfunction on dose reduction and virologic efficacy of regimens combining ribavirin and all-oral direct acting antivirals in patients with chronic hepatitis C virus infection

Hepatol Res　49,P.512-520　/　2019

Nakashima M, Toyoda H, Tada T, Mizuno K, Iio E, Tanaka Y, Sugiyama T, Yoshimura T, Kumada T

Independent and additive effects of PNPLA3 and TM6SF2 polymorphisms on the development of non-B, non-C hepatocellular carcinoma

J Gastroenterol　54,P.427-436　/　2019

Raksayot M, Chuaypen N, Khlaiphuengsin A, Pinjaroen N, Treeprasertsuk S, Poovorawan Y, Tanaka Y, Tangkijvanich P

Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk

Aliment Pharmacol Ther　49,P.107-115　/　2019

Hsu Y-C, Nguyen MH, Mo L-R, Wu M-S, Yang T-H, Chen C-C, Tseng C-H, Tai C-M, Wu C-Y, Lin J-T, Tanaka Y, Chang C-Y

TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus by interferon-free therapy

J Gastroenterol　54,P.339-346　/　2019

Iio E, Matsuura K, Shimada N, Atsukawa M, Itokawa N, Abe H, Kato K, Takaguchi K, Senoh T, Eguchi Y, Nomura H, Yoshizawa K, Kang J-H, Matsui T, Hirashima N, Kusakabe A, Miyaki T, Fujiwara K, Matsunami K, Tsutsumi S, Iwakiri K, Tanaka Y

Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy

Blood　133,P.137-146　/　2019

Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, Peters MG, Tanaka Y, Zelenetz AD, Kuriki H, Fingerle-Rowson G, Nielsen T, Ueda E, Piper-Lepoutre H, Sellam G, Tobinai K

Efficacy of direct-acting antiviral treatment in patients with compensated liver cirrhosis: A multicenter study

Hepatol Res　49,P.125-135　/　2019

Itokawa N, Atsukawa M, Tsubota A, Ikegami T, Shimada N, Kato K, Abe H, Okubo T, Arai T, Iwashita A-N, Kondo C, Mikami S, Asano T, Matsuzaki Y, Toyoda H, Kumada T, Iio E, Tanaka Y, Iwakiri K

Efficacy and safety of sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial

J Gastroenterol　54,P.87-95　/　2019

Takehara T, Sakamoto N, Nishiguchi S, Ikeda F, Tatsumi T, Ueno Y, Yatsuhashi H, Takikawa Y, Kanda T, Sakamoto M, Tamori A, Mita E, Chayama K, Zhang G, De-Oertel S, Dvory-Sobol H, Matsuda T, Stamm LM, Brainard DM, Tanaka Y, Kurosaki M

Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study

J Gastroenterol Hepatol　34,P.364-369　/　2019

Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Kondo C, Okubo T, Hiraoka A, Michitaka K, Fujioka S, Uojima H, Watanabe T, Ikeda H, Asano T, Ishikawa T, Matsumoto Y, Abe H, Kato K, Tsuji K, Ogawa C, Shimada N, Iio E, Mikami S, Tanaka Y, Kumada T, Iwakiri K

An Association Between Core Mutations in Hepatitis B Virus Genotype F1b and Hepatocellular Carcinoma in Alaskan Native People

Hepatology　69,P.19-33　/　2019

Hayashi S, Khan A, Simons BC, Homan C, Matsui T, Ogawa K, Kawashima K, Murakami S, Takahashi S, Isogawa M, Ikeo K, Mizokami M, McMahon BJ, Tanaka Y